Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Tavilermide by Mimetogen Pharmaceuticals for Keratoconjunctivitis Sicca (Dry Eye): Likelihood of Approval
Tavilermide is under clinical development by Mimetogen Pharmaceuticals and currently in Phase III for Keratoconjunctivitis Sicca (Dry Eye). According to...